

117TH CONGRESS 1ST SESSION

H.R.

To amend the United States-Mexico Border Health Commission Act, with respect to preparedness for COVID-19 and other infectious diseases in the border region, and for other purposes.

IN THE HOUSE OF REPRESENTATIVES

Ms. Escobar introduced the following bill; which was referred to the Committee on _____

A BILL

To amend the United States-Mexico Border Health Commission Act, with respect to preparedness for COVID-19 and other infectious diseases in the border region, and for other purposes.

- 1 Be it enacted by the Senate and House of Representa-
- 2 tives of the United States of America in Congress assembled,
- 3 SECTION 1. SHORT TITLE.
- 4 This Act may be cited as the "Binational Health
- 5 Strategies Act of 2021".

| 1 | SEC. 2. UNITED STATES-MEXICO BORDER HEALTH COMMIS- |
|----|---|
| 2 | SION INFECTIOUS DISEASE PREPAREDNESS. |
| 3 | The United States-Mexico Border Health Commis- |
| 4 | sion Act (22 U.S.C. 290n et seq.) is amended by inserting |
| 5 | after section 4 (22 U.S.C. 290n–2) the following: |
| 6 | "SEC. 4A. INFECTIOUS DISEASE PREPAREDNESS. |
| 7 | "(a) Presidential Negotiations.—The President |
| 8 | is authorized and directed to, not later than 30 days after |
| 9 | the date of the enactment of this section, seek to begin |
| 10 | negotiations with Mexico to amend the agreement entered |
| 11 | into pursuant to section 2, addressing infectious disease |
| 12 | preparedness in the United States-Mexico Border Area, |
| 13 | with respect to— |
| 14 | "(1) COVID-19, including the development of |
| 15 | the report specified in subsection (b) and the plan |
| 16 | specified in subsection (c); and |
| 17 | "(2) other infectious diseases, including the de- |
| 18 | velopment and implementation of the plan specified |
| 19 | in subsection (d). |
| 20 | "(b) COVID-19 RESPONSE.—Not later than 120 |
| 21 | days after the date on which negotiations referred to in |
| 22 | subsection (a) begin, and annually thereafter (for as long |
| 23 | as the Commission, acting with the participation of mem- |
| 24 | bers representing both the United States and Mexican sec- |
| 25 | tions, determines is necessary), the Commission shall sub- |
| 26 | mit to Congress a report on the United States-Mexico Bor- |

| 1 | der Area's response (beginning on February 1, 2020) to |
|----|--|
| 2 | COVID-19, including with respect to testing, contact trac- |
| 3 | ing, and other infection prevention and control measures |
| 4 | carried out in the United States-Mexico Border Area, in |
| 5 | both the United States and Mexico. |
| 6 | "(c) COVID-19 BINATIONAL PLAN.— |
| 7 | "(1) In general.—Not later than 60 days |
| 8 | after the date on which negotiations referred to in |
| 9 | subsection (a) begin, the Commission (acting with |
| 10 | the participation of members representing both the |
| 11 | United States and Mexican sections) shall develop, |
| 12 | and publish on a public website of the Commission, |
| 13 | a binational strategic plan that addresses, with re- |
| 14 | spect to COVID-19, how— |
| 15 | "(A) the United States-Mexico Border |
| 16 | Area should strengthen its response to COVID- |
| 17 | 19, with a focus on testing, contact tracing, and |
| 18 | other infection prevention and control measures; |
| 19 | "(B) the effect of COVID-19 on the eco- |
| 20 | nomic conditions in the United States-Mexico |
| 21 | Border Area may be mitigated; |
| 22 | "(C) the sharing of relevant health data, |
| 23 | with respect to COVID-19, including testing |
| 24 | and positivity rates, between health agencies |

| 1 | within the United States-Mexico Border Area |
|----|---|
| 2 | can be strengthened; and |
| 3 | "(D) a COVID-19 vaccine should be dis- |
| 4 | bursed throughout the United States-Mexico |
| 5 | Border Area, taking into account the various |
| 6 | vulnerable populations in the region. |
| 7 | "(2) Implementation.—Not later than 90 |
| 8 | days after the date on which negotiations referred to |
| 9 | in subsection (a) begin, the Commission (acting with |
| 10 | the participation of members representing both the |
| 11 | United States and Mexican sections) shall develop, |
| 12 | and publish on a public website of the Commission, |
| 13 | what actions Federal agencies will take within the |
| 14 | United States section and agencies of the Govern- |
| 15 | ment of Mexico will take within the Mexican section |
| 16 | of the United States-Mexico Border Area to facili- |
| 17 | tate implementation of the plan under paragraph |
| 18 | (1). At least once each year after the publication of |
| 19 | such information, the Commission shall submit to |
| 20 | Congress a report on actions taken by Federal agen- |
| 21 | cies and agencies of the Government of Mexico to fa- |
| 22 | cilitate that implementation during the year covered |
| 23 | by the report. |
| 24 | "(d) Future Infectious Disease Plan.— |

| 1 | "(1) In general.—Not later than 180 days |
|----|---|
| 2 | after the date on which negotiations referred to in |
| 3 | subsection (a) begin, the Commission shall develop |
| 4 | and publish a plan to prepare and respond to infec- |
| 5 | tious diseases (other than COVID-19) within the |
| 6 | United States-Mexico Border Area. Such plan shall |
| 7 | address how— |
| 8 | "(A) the United States-Mexico Border |
| 9 | Area should strengthen its response to such in- |
| 10 | fectious diseases, with a focus on testing, con- |
| 11 | tact tracing, and other infection prevention and |
| 12 | control measures; |
| 13 | "(B) the effect of such infectious diseases |
| 14 | on the economic conditions in the United |
| 15 | States-Mexico Border Area may be mitigated; |
| 16 | "(C) the sharing of relevant health data, |
| 17 | with respect to such infectious diseases, includ- |
| 18 | ing testing and positivity rates, between health |
| 19 | agencies within the United States-Mexico Bor- |
| 20 | der Area can be strengthened; and |
| 21 | "(D) a vaccine for such infectious diseases |
| 22 | should be disbursed throughout the United |
| 23 | States-Mexico Border Area, taking into account |
| 24 | the various vulnerable populations in the region. |

| 1 | "(2) UPDATES.—The Commission shall update |
|----|---|
| 2 | the plan published under paragraph (1) at least once |
| 3 | every 3 years for as long as the Commission, acting |
| 4 | with the participation of members representing both |
| 5 | the United States and Mexican sections, determines |
| 6 | is necessary. |
| 7 | "(3) Implementation.—Not later than 210 |
| 8 | days after the date on which negotiations referred to |
| 9 | in subsection (a) begin, the Commission (acting with |
| 10 | the participation of members representing both the |
| 11 | United States and Mexican sections) shall develop |
| 12 | and publish on a public website of the Commission |
| 13 | what actions Federal agencies will take within the |
| 14 | United States section and agencies of the Govern- |
| 15 | ment of Mexico will take within the Mexican section |
| 16 | of the United States-Mexico Border Area to facili- |
| 17 | tate implementation of the plan under paragraph |
| 18 | (1). At least once a year after the publication of |
| 19 | such information, the Commission shall submit to |
| 20 | Congress a report on actions taken by Federal agen- |
| 21 | cies and agencies of the Government of Mexico to fa- |
| 22 | cilitate that implementation during the year covered |
| 23 | by the report. |
| 24 | "(e) Definitions.—In this section: |

| 1 | "(1) COVID-19.—The term 'COVID-19' refers |
|---|--|
| 2 | to the 2019 coronavirus disease caused by SARS- |
| 3 | CoV-2. |
| 4 | "(2) SARS-cov-2.—The term 'SARS-CoV-2' |
| 5 | refers to the severe acute respiratory syndrome |
| 6 | coronavirus 2 virus responsible for COVID-19 and |
| 7 | includes any viral variant mutating therefrom with |
| 8 | pandemic potential.". |